AI in Drug Discovery & Development

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael, Senior Business & Finance Editor

Hype, Reality, and What Comes Next

IndustryLife Sciences & Healthcare

AI has emerged as a powerful potential solution that could revolutionize how drugs are discovered, developed, and brought to patients. AlphaSense recently hosted an expert call with Dr. Paul Agapow, Former Director of Data Science at GSK, to discuss how AI is making inroads in this area.

Drawing from the call with Dr. Agapow, the latest data, and additional expert insights, this report covers how AI is performing against high expectations, what’s working, and what's not. This report also dissects the competitive arena, covering both today’s key players and the mergers, acquisitions, and collaborations that are defining the future.

About the Authors

Sara Mallatt, Director of Healthcare Research
Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
Sean Carmichael, Senior Business & Finance Editor
Sean is a Senior Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.